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A B S T R A C T
Purpose: This study aimed to compare the clinical outcomes of immunotherapy with dendritic cell (DC) vaccine
and cytokine-induced killer (CIK) cells with those of radiotherapy in non-small cell lung cancer (NSCLC).
Methods: The immunotherapy group included 197 NSCLC patients with stage IIIb–IV disease, loco-regional
recurrence, or distant metastasis after surgery who received immunotherapy with DC vaccine and CIK cells.
Delayed type hypersensitivity (DTH) skin test results, quality of life (QOL), and safety were analyzed. The well-
balanced control group included 192 patients receiving radiotherapy. All patients were followed-up for 569.87
± 295.52 days for overall survival (OS) analysis using the Kaplan-Meier method.
Results: DTH results, QOL, and side eﬀects data were available for 197 patients in the immunotherapy group.
One hundred and twenty-one of these (61.42%) developed a positive immune response to immunotherapy
evidenced by the DTH skin test, and 180 (91.37%) had improved QOL. Fever was observed in 67 patients
(34.01%), insomnia in 86 (43.65%), anorexia in 71(36.04%), joint soreness in 33 (16.75%), and skin rash in
seven (3.55%). No server toxicities were observed in the immunotherapy group. Compared with the control
group, OS was signiﬁcantly prolonged in the immunotherapy group (P=0.000). OS rates at 6, 12, and 18 months
were 88.8%, 82.2%, and 79.6% in the immunotherapy group and 73.4%, 64.1%, and59.3% in the control group,
respectively.
Conclusions: Immunotherapy with DC vaccine and CIK cells might induce an immune response against
NSCLC, improve QOL, and oﬀer a survival beneﬁt without severe toxicity in NSCLC patients, compared to
radiotherapy.
1. Introduction
Lung cancer is the most common cause of death from cancer
malignancy in the world. Among them, non-small cell lung cancer
(NSCLC) accounts for about 80% of all cases [1]. Surgery, radiotherapy,
and chemotherapy remain the standard therapeutic options for NSCLC
patients [2]. However, most of them are not suitable for surgery
because they are often diagnosed at an advanced stage (stage IIIb or
IV) [3,4]. Furthermore, patients undergoing radical surgery might
eventually develop loco-regional recurrence or distant metastasis [5,6].
Advanced NSCLC is highly malignant and characterized by inexorable
disease progression. Its prognosis is poor, despite chemotherapy and/
or radiation. Although systemic chemotherapy is recommended as the
ﬁrst-line treatment for patients with advanced stage and metastatic
NSCLC, it is often considered ineﬀective or excessively toxic [7,8].
Therefore, new treatment modalities for NSCLC are urgently needed,
and immunotherapy has been developed as a potential option [9].
Additionally, multidisciplinary therapy is generally accepted as a
possibility for the treatment of advanced NSCLC [10].
Immunotherapy has been suggested as an important and eﬃcient
therapeutic option for cancer patients, especially those with late-stage
disease [11]. Immune response cells such as cytokine-induced killer
(CIK) cells and dendritic cells (DC) might participate in the develop-
ment of an eﬀective immune response against cancer cells and help
eliminate them [12–14]. The combination of conventional treatment
such as surgery, chemotherapy, and radiotherapy with immunotherapy
might be a novel approach to anti-cancer therapy for the ultimate goal
of reducing mortality [2,15].
In the present study, we evaluated the immune response induced by
immunotherapy with DC vaccine and CIK cells in advanced NSCLC
patients. Improvements in patients' quality of life (QOL) and treat-
ment-related side eﬀects were also assessed. Furthermore, the overall
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survival (OS) of patients receiving immunotherapy or radiotherapy (the
control group) was compared to analyse the potential survival beneﬁt
from DC vaccine and CIK cells in advanced NSCLC.
2. Patients and methods
2.1. Study design
The present investigation was a retrospective clinical study ﬁnished
at the Department of Oncology, Tianjin Union Medicine Centre,
Tianjin, China. All patients were referred to our department between
January 4, 2012 and June 30, 2013. The study protocol was approved
by our institutional ethics committees, and class III medical techniques
of “Treatment with autologous immune cells (T cells or NK cells)” were
performed in accordance with the Minister of Health of China policy.
All patients provided written informed consent before receiving treat-
ment.
2.2. Patients
Inclusion criteria were as follows: (1) hospitalization for immu-
notherapy with DC vaccine and CIK cells for NSCLC between January
4, 2012 and June 30, 2013; (2) unresectable NSCLC and loco-regional
recurrence or distant metastasis after surgery; and (3) adequate
function of the kidneys, liver, coagulation, and bone marrow. (4)
Patients wth chemotherapy (if any) of TP regimen were included (T:
paclitaxel or docetaxel; P: cisplatin or carboplatin). Patients who met
these criteria were enrolled as the immunotherapy group, whereas the
control group included patients receiving radiotherapy who had well-
balanced characteristics compared to those in the immunotherapy
group.
2.3. Preparation of immunocytes
Immunocytes, including DCs and CIK cells, were prepared as
previously described [16–18]. The Fresenius KABI System was used
to collect the peripheral blood mononuclear cells (PBMCs) through a
process of leukapheresis. Then, PBMCs were cultured with serum-free
medium overnight. Adherent cells (consisting of monocytes) and non-
adherent cells (consisting of lymphocytes) were then separated. Scine
only 15.93% patients (62/389) underwent primary tumor resection,
the autologous tumor lysates could not be gtten. Two lung cancer cell
lines, SPC-A-1 for adenocarcinoma and SK-MES-1 for squamous cell
carcinoma, were cultured for 24 h at 37 °C, ultrasonicated, and
centrifuged at 600g for 30 min. Tumour lysate was obtained by
collecting the supernatant and used for pulsing DCs and delayed type
hypersensitivity (DTH) testing.
Under the activating with granulocyte-macrophage colony-stimu-
lating factor, interleukin (IL) 4, tumour lysate,and tumour necrosis
factor for 7 days, DC vaccine was prepared by culturing the adherent
cells [19,20]. CIK cells were prepared by culturing the non-adherent
cells in the presence of interferon gamma, CD3 monoclonal antibody,
and IL-2 for 11 to 14 days [21].
2.4. Quality control of immunocytes
The immune phenotypes were analysed by ﬂow cytometry through
expression of HLA2DR, CD80, and CD83 for DCs and CD3, CD8, and
CD56 for CIK cells. The cultured samples of DCs and CIK cells were
checked to ensure no bacterial or fungal contamination, and the
endotoxin levels were less than 5 EU/kg. Intradermal vaccination with
DCs was administered using 1×107 cells. For intravenous vaccination,
DCs were solubilized in 100 ml of normal saline (NS) for intravenous
vaccination. CIK cells were infused intravenously using 1×109 cells in
100 ml NS. For more detailed information on quality control of
immunocytes, please refer to our published papers [17].
2.5. Reinfusion of immunocytes
PBMCs were collected on day 0 of the treatment schedule.
Subsequently, 1×107 DCs were intravenously infused once a week for
6 weeks starting from day 8, and 1×109 CIK cells were intravenously
infused once a day for 4days from days 11 to 14.
2.6. DTH
DTH tests were conducted one week after the last DC vaccination by
intradermal injection of 4 μg of tumour lysate. After 48 h, the tests
were read. Based on the diameter of induration, the results were graded
as follows: strongly positive, > 10 mm; positive, 5–10 mm; weakly
positive, 2–5 mm, and negative, < 2 mm [22].
2.7. QOL
The general status of physical strength, appetite, sleeping, and body
weight was evaluated as indexes of improved QOL. The number of
improved indexes were reported, with 1–4 improved indexes being
considered as a progress of patients' general status results [23,24].
2.8. Safety
During the process of immunotherapy, fever, insomnia, anorexia,
joint soreness, and skin rash were considered as the side eﬀects [25].
2.9. OS
All patients were followed-up until September 30, 2014. OS was
calculated from the date of study enrolment to that of death. Data on
patients who were lost to follow-up with an uncertain cause of death or
unconﬁrmed date of death were censored. This deﬁnition might result
in the number of dead patients to be the same degree of less than the
actual in both experimental group and control group.
2.10. OS rates
The OS rates at 6, 12, and 18 months were calculated for both
patient groups.
2.11. Data collection and statistical analysis
OS was the primary eﬃcacy end point, meanwhile DTH results,
QOL, and safety were the secondary end points for this study. Clinical
data were collected from the Inpatient Electronic Medical Records of
our hospital, re-analysed, and documented to conform to the aims of
this study using Epidata database (version 3.02). All statistical analyses
were performed using SPSS (version 19.0, IBM SPSS, Chicago, IL,
USA), docked with Epidata database (version 3.02, EpiData
Association, Odense, Denmark). OS curves were generated using the
Kaplan-Meier method. The P value of less than 0.05 was selected as
statistically signiﬁcant.
3. Results
3.1. Patient characteristics
The study cohort included 389 patients with advanced NSCLC. The
patients’ mean age was 66.17 ± 10.59 (range, 30–89) years. There were
238 men and 151 women. Tumour burden was observed in 337
patients, including locoregional recurrence in 197 and distant metas-
tasis in 140. The tumor burdern in the other 52 patients were
eliminated by chemotherapy before inclusion. The tumour type was
adenocarcinoma in 219 patients, squamous cell carcinoma in 145, and
undeﬁned in twenty-ﬁve. The tumour grade was good in forty-three
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patients, intermediate in 176, and poor in 190. Of the 389 patients, 62
(15.93%) underwent primary tumor resection, 81 (20.82%) received
chemotherapy. Patients wth chemotherapy (if any) of TP regimen were
included (T: paclitaxel or docetaxel; P: cisplatin or carboplatin). The
experimental group included 197 patients who received
Immunotherapy,and the control group included 192 patients who
received radiotherapy. Patient characteristics were well balanced
between the two groups for the items evaluated, except for treatment
modality (immunotherapy or radiotherapy) (Table 1).
3.2. DTH
Of the 197 enrolled patients in the immunotherapy group, 197
underwent the DTH skin test, including 34 (17.26%) with strongly
positive, 59 (29.95%) with positive, and 28 (14.21%) with weakly
positive results. In general, 61.42% of all patients (121 of 197)
developed a positive DTH skin test, and 38.58% (76 of 197) had a
negative result (Table 2).
3.3. QOL
QOL was assessed via the improvement of patients' general status,
including physical strength, appetite, sleeping, and body weight, in 197
immunotherapy group patients. Of these, 32 patients (16.24%) showed
improvements in all four QOL indexes, 55 (27.92%) showed improve-
ments in three indexes, 64 (32.49%) showed improvements in two
indexes, 29 (14.72%) showed improvement in one index, and 17
(8.63%) presented no QOL improvement. Thus, 91.37% (180/197) of
all patients enjoyed improved QOL (Table 3).
3.4. Safety
Side eﬀects were observed in 197 patients receiving immunother-
apy. Fever was observed in 67 patients (34.01%), insomnia in 86
(43.65%), anorexia in 71 (36.04%), joint soreness in 33 (16.75%), and
skin rash in seven (3.55%). No severe toxicities was observed in the
immunotherapy group (Table 4).
3.5. OS
All patients were followed-up for 569.87 ± 295.52 days. By the end
of the follow-up period (September 30, 2014), 45 patients in the
immunotherapy group and 85 in the control group had died of NSCLC.
Kaplan-Meier survival analysis revealed that the OS of the immu-
notherapy group was signiﬁcantly longer than that of the control group
(P=0.000, Fig. 1).
3.6. OS rates
The OS rates at 6, 12, and 18 months in the immunotherapy group
were 88.8%, 82.2%, and 79.6% respectively, whereas those in the
control group were 73.4%, 64.1%, and 59.3%, respectively (P=0.000,
Table 5).
4. Discussion
The therapeutic eﬃcacy of conventional cancer treatment modal-
ities, such as surgery, radiotherapy, and chemotherapy, remains very
poor for NSCLC despite their rapid development. [26] Therefore, the
development of novel treatment, including immunotherapy with DC
vaccine and CIK cells, is urgently needed to improve the clinical
outcomes of NSCLC patients. Several studies have reported that DCs
could activate CIK cells to enhance antitumor eﬀects in patients with
NSCLC [27,28]. Adoptive transfer of CIK cells with DCs has been
demonstrated as a signiﬁcantly important strategy to improve OS
[29,30]. DC vaccine and CIK cells act to enhance the host cellular
immune responses [31], regulate the immune interaction between
Table 1
Patient characteristics.
Characteristic Immunotherapy
group
Control
group
Total P value
No. of patients (death) 197 (45) 192 (85) 389
(130)
Age, y 0.721
Range 30–89 34–87 30–89
Mean ± SD 65.76 ± 10.81 66.59 ±
10.37
66.17 ±
10.59
Sex, n 0.826
Male 120 118 238
Female 77 74 151
Tumour burden, n 0.465
None 30 22 52
Locoregional
recurrence
95 102 197
Distant metastasis 72 68 140
Tumour type, n 0.904
Adenocarcinoma 130 89 219
Squamous cell
carcinoma
83 62 145
Undeﬁned 14 11 25
Tumour grade, n 0.664
Good 19 24 43
Intermediate 90 86 176
Poor 88 82 190
Treatment baseline 0.733
Surgery 34 25 62
aChemotherapy 49 32 81
Radiotherapy 0 192 192
Immunotherapy 197 0 197
a Patients wth chemotherapy (if any) of TP regimen were included. (T: paclitaxel or
docetaxel; P: cisplatin or carboplatin).
Table 2
Results of delayed-type hypersensitivity skin test in the immunotherapy group (n=197).
Result Definition, mm n (%)
Strongly positive > 10 34 (17.26)
Positive 5–10 59 (29.95)
Weakly positive 2–5 28 (14.21)
Negative < 2 76 (38.58)
Table 3
Quality of life (QOL) in the immunotherapy group (n=197).
No. of improved QOL indices n (%)
4 32 (16.24)
3 55 (27.92)
2 64 (32.49)
1 29 (14.72)
0 17 (8.63)
General status of physical strength, appetite, sleep, and body weight were evaluated as
indices of QOL. Results of QOL were defined as follows: 0=none of the 4 indices, 1=any 1
of the 4 indices, 2=any 2 of the 4 indices, 3=any 3 of the 4 indices, 4=all the 4 indices.
Table 4
Adverse effects observed in the immunotherapy group (n=197).
Adverse eﬀect n (%)
Fever 67 (34.01)
Insomnia 86 (43.65)
Anorexia 71 (36.04)
Joint soreness 33 (16.75)
Skin rash 7 (3.55)
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patients and their tumours, and thus prolong their survival and
improve their QOL [24].
Similar to chemotherapy, immunotherapy with DC vaccine and CIK
cell may have beneﬁt eﬀects on survival in colorectal cancer (CRC)
patients, reported in our previous study [32]. In resectable CRC, MST
was signiﬁcantly longer (92 days) in the immunotherapy group (in
which, patients received primary tumor resection and followed by both
adjuvant chemotherapy and immunotherapy ) than that in the control
group (in which, patients received primary tumor resection and
followed by adjuvant chemotherapy alone ). In advanced CRC, MST
was signiﬁcantly longer (154 days) in the immunotherapy group (in
which, patients received chemotherapy plus immunotherapy) than that
in the control group (in which, patients received chemotherapy alone).
In the present study, we observed promising outcomes by immu-
notherapy with DC vaccine and CIK cells, resulting in improved OS and
QOL in advanced NSCLC patients, which further conﬁrmed the
potential of this novel treatment modality. We also demonstrated via
clinical observations that the DTH skin test was eﬀective in evaluating
the cell-mediated cytotoxicity response induced by immunotherapy.
But, there were no diﬀerence in the survival of patients who developed
a positive tumor-speciﬁc DTH response compared with patients who
had a negative DTH test, illustrated by our data (showed in Fig. 2) and
reported by others [22]. Patients in control group did not receive
immunotherapy, and there were no changes of cell-mediated cytotoxi-
city immune response. DTH did not used as a routine index in patients
not received immunotherapy clinically. As a clinical retrospective
study, there were no data on DTH skin test in control group could be
collected. In this study, tumor cell lines were used to form the tumor
lysates, which might contaminate with impurities. It was unclear
whether the DTH responses were tumor speciﬁc or others. It would
be of interest if a DTH was undertaken prior to initiation of
immunization and 2-4 weeks after completion of immunization, and
the control population also undergo DTH analysis, and worth further
study.
Now, cancer treatment with autologous immune cells (T cells or NK
cells) became as a clinical routine treatment project in our hospital.
Our team engaged in clinical retrospective study of autoimmunocyte
therapy from 2012, and published several papers about immunother-
apy. The safety of immunotherapy was reported in our earlier paper
[15] and also reported by others [36]. The side eﬀects were fever,
allergies, joint pain, insomnia and anorexia. Based on clinical data
collected on immunotherapy from January 4, 2012 to June 30, 2015,
the treatment related side eﬀects in total 5808 cases were mainly fever
(33.51%), occasional systemic allergic skin rash (2.52%), and some
nonspeciﬁc side eﬀects (about 22.19%), including joint pain, insomnia,
anorexia, etc. No and other serious side eﬀects on heart, liver, kidney
and myelosuppression, etc. were observed (more in detailed data are
not showed).
Based on the observation illustrated in this paper, no severe side
eﬀects were observed during DC vaccine and CIK cell transfusion,
conﬁrming the treatment safety. The side eﬀects reported in our study
were minor and could be eﬀectively managed. Fever was common
during the treatment process. However, it was mild and temporary in
most cases with body temperature below 39 °C and easily relieved by
physical cooling or antipyretic analgesics. In addition, allergic reaction
characterized by skin rash was rare, usually mild, and self-resolving
without any special treatment [33].
In the present study, we observed immunotherapy using DC
Fig. 1. Kaplan-Meier curves for overall survival in both groups. By the time of this
analysis, the immunotherapy group (n = 197) had 45 deaths, whereas the control group
(n=192) had 85 deaths (X2=22.11, P=0.000).
Table 5
Overall survival rates in the immunotherapy and control groups (P=0.023).
Group No. of patients Deaths, n Overall survival rate, % Total
6-month 12-month 18-month
Immunotherapy 197 45 88.8 82.2 79.6 77.2
Control 192 85 73.4 64.1 59.3 55.7
Total 389 130 81.2 73.3 69.6 66.6
Fig. 2. Kaplan-Meier curves for overall survival in both groups. By the time of this
analysis, the DTH positive group (n=121) had 25 deaths, whereas the DTH negative
group (n=76) had 20 deaths (X2=0.695, P=0.404).
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vaccination and CIK cells could prolong OS and improved QOL,
resulting in improving the clinical outcomes of advanced NSCLC
patients [34,35].
5. Conclusions
There were no severe side eﬀects with immunotherapy using DC
vaccination and CIK cells, which could stimulate responses by the
patients' own immune system against cancer [34,36,18]. Therefore, its
combination with conventional cancer treatment modalities might
improve the clinical outcomes of advanced NSCLC patients, resulting
in prolonged OS and improved QOL.
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